^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)

    i
    Other names: NTRK2, TRKB, Neurotrophic tyrosine kinase, receptor, type 2
    1d
    Firmonertinib for Adjuvant Therapy in Completely Resected Stage IA EGFR-Mutated NSCLC (ChiCTR2600121611)
    P4, N=535, Recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
    New P4 trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RB1 (RB Transcriptional Corepressor 1) • FGFR (Fibroblast Growth Factor Receptor) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • ALK positive • RET fusion • ALK fusion • FGFR mutation • RET mutation • ROS1 fusion • MET mutation • RB1 mutation • NRG1 fusion • KRAS G12 • BRCA mutation
    |
    Ivesa (firmonertinib)
    4d
    NTRK fusions and concomitant immune and genomic landscape detected by DNA and RNA comprehensive genomic profiling in a large healthcare system. (PubMed, Front Med (Lausanne))
    These findings highlight the value of RNA-based NGS, particularly when used alongside DNA NGS, to provide a comprehensive assessment of NTRK fusions and co-occurring gene alterations. Implementation of combined DNA and RNA CGP in a community health system setting enables detection of both known and novel NTRK fusions and can inform clinical care of cancer patients.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    9d
    Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=73, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    10d
    Skeletal muscle lysate derived macroporous hydrogel repairs spinal cord injury via immunoregulation and axon regeneration. (PubMed, Biomater Adv)
    In vivo, it induces early recruitment of endogenous neural progenitor cells (NPCs) into the scaffold, promotes neuronal and oligodendrocyte differentiation, inhibits glial scar formation, and facilitates axonal and myelin regeneration, ultimately improving functional recovery in mice. As an autologous skeletal muscle-derived biomaterial with significant therapeutic potential for SCI repair, MTLH represents a promising strategy for clinical translation in SCI treatment.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • IL17A (Interleukin 17A)
    10d
    Functional Mapping of Neurodevelopmental Disease Pathways to Key Neurodevelopmental Processes Represented in the Developmental Neurotoxicity In Vitro Testing Battery. (PubMed, Adv Sci (Weinh))
    Pathway-KNDP associations are integrated into an exemplary interactive physiological map of human oligodendrocyte development, linking mechanistic perturbations to human-relevant biology. Defining which NDD pathways can be functionally probed refines the DNT IVB's biological applicability domain, increases confidence in its protective power, and supports mechanistic interpretation of new approach methodology-based DNT assessment.
    Preclinical • Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STAT3 (Signal Transducer And Activator Of Transcription 3) • RHOA (Ras homolog family member A)
    11d
    Epigenetic Regulation of Trk Receptors and Neurotrophic Signalling in Neuroblastoma: Mechanisms, Plasticity, and Therapeutic Opportunities. (PubMed, Int J Mol Sci)
    We discuss advanced three-dimensional and organoid-based models that recapitulate niche-specific regulation of the Trk axis and evaluate emerging therapeutic strategies combining epigenetic modulators, differentiation-inducing agents, and RTK-targeted compounds. Understanding the temporal and spatial dynamics of Trk signalling may open new opportunities to therapeutically stabilise differentiation states and disrupt adaptive resistance programs in high-risk NB.
    Review • Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NGFR (Nerve Growth Factor Receptor) • NTRK (Neurotrophic receptor tyrosine kinase)
    12d
    Molecular landscape and biomarker associations of functional NTRK fusions: a real-world retrospective cohort study across solid tumors. (PubMed, Transl Cancer Res)
    Functional NTRK fusion-positive tumors comprise biologically and clinically distinct subsets defined by tumor type and MSI/TMB context. Concurrent reporting of MSI/TMB (and HRD/EBV when available) together with NTRK fusion status may facilitate integrated clinical interpretation, support precision treatment selection, and refine trial stratification in clinical practice.
    Retrospective data • Journal • Real-world evidence • Tumor mutational burden • MSi-H Biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRD (Homologous Recombination Deficiency) • ETV6 (ETS Variant Transcription Factor 6) • RNF43 (Ring Finger Protein 43) • TPM3 (Tropomyosin 3) • NTRK (Neurotrophic receptor tyrosine kinase) • ACVR2A (Activin A Receptor Type 2A)
    |
    MSI-H/dMMR • HRD • NTRK positive • NTRK fusion
    15d
    MoST Addendum 6: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 6 substudy 14-15: Larotrectinib (ACTRN12619001147178)
    P2, N=32, Completed, The University of Sydney | Active, not recruiting --> Completed
    Trial completion
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    Vitrakvi (larotrectinib)
    23d
    Synergistic inhibition of tumor growth by MET and COX-2 targeting in gastric and colorectal cancers. (PubMed, Bioorg Chem)
    In animal models, AspMet significantly reduced the growth of subcutaneous tumors in both gastric and colorectal cancers，and it has an extremely high bioavailability. Therefore, the dual inhibition strategy targeting c-Met and COX-2 offers a promising novel approach for the treatment of cancers, particularly inflammatory cancers.
    Journal
    |
    NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HIF1A (Hypoxia inducible factor 1, alpha subunit)
    24d
    The Evaluation of Neurotrophic Receptor Tyrosine Kinase (NTRK) Alterations in Neuroblastomas. (PubMed, Front Biosci (Schol Ed))
    Owing to the presence of neural tissue, NTRKs are highly positive in IHC, making these genes unsuitable as biomarkers for assessing NTRK inhibitor sensitivity and resistance, which are tissue-agnostic drugs. The observed low fusion rate is consistent with the literature, and the significance of the numerous point mutations identified as agnostic markers warrants further investigation. NTRK expression, fusion, and point mutations were not associated with clinical parameters or survival.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    Chr del(11q) • MYCN amplification • NTRK positive • NTRK fusion
    |
    Vitrakvi (larotrectinib) • Rozlytrek (entrectinib)
    26d
    BT8009-202: Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer (2025-521115-40-00)
    P1/2, N=28, Active, not recruiting, Bicycletx Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    zelenectide pevedotin (BT8009)
    28d
    Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=230, Not yet recruiting, Swiss Cancer Institute | Initiation date: Dec 2025 --> Jul 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CD4 (CD4 Molecule)
    |
    BRAF V600E • HER-2 amplification • BRAF V600 • HER-2 mutation • RET mutation • RET rearrangement